Today: 19 April 2026
Subscribe
Browse Category

NASDAQ:NBIX 7 April 2026

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics withdrew its European filing for VIOKAT on Tuesday, halting a regulatory review that was expected to conclude in 2026. The move came one day after Neurocrine Biosciences agreed to acquire Soleno for $2.9 billion in cash, or $53 a share. Vykat XR, Soleno’s only marketed product, generated $190.4 million in 2025 U.S. sales. Neurocrine said it has no immediate plans for a European launch.
7 April 2026
···
Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR

Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR

Neurocrine Biosciences will acquire Soleno Therapeutics for $53 a share in cash, valuing Soleno at $2.9 billion. The deal gives Neurocrine Vykat XR, the only FDA-approved treatment for hyperphagia in Prader-Willi syndrome. Soleno shares last traded at $52.25. The transaction is expected to close within 90 days, pending regulatory and shareholder approval.
7 April 2026
···

Stock Market Today

  • Are These 10 ASX Stocks With Low PE Multiples Genuine Value Buys?
    April 19, 2026, 4:05 PM EDT. This report examines 10 ASX stocks trading at low price-to-earnings (P/E) multiples, a metric used to assess whether shares are undervalued. Analysts caution that low P/E ratios can result from market skepticism or accounting distortions but identify these 10 names as having broadly genuine earnings power. Notable among them is Pepper Money (ASX:PPM) with a forward P/E of about 9.4 and diversified lending operations, though market concerns over credit risk remain. FleetPartners (ASX:FPR) trades at an even lower forward P/E near 6.8, driven by stable cash flows but facing residual-value risks tied to the used-vehicle market. The study underscores that while these stocks appear undervalued, investor caution reflects real risks rather than accounting artifacts.

Latest article

QXO to Buy TopBuild for $17 Billion in Brad Jacobs’ Biggest Building-Products Push Yet

QXO to Buy TopBuild for $17 Billion in Brad Jacobs’ Biggest Building-Products Push Yet

19 April 2026
QXO said Sunday it will acquire TopBuild for about $17 billion in cash and stock, offering TopBuild shareholders $505 per share or 20.2 QXO shares each, with a 45% cash and 55% stock mix. The deal values TopBuild at a 23% premium to Friday’s close. The combined company is expected to generate over $18 billion in revenue and close the transaction in the third quarter, pending shareholder approval.
Social Security 2027 COLA Forecast Holds at 2.8%, but Retirees May Get Less Relief Than They Hope

Social Security 2027 COLA Forecast Holds at 2.8%, but Retirees May Get Less Relief Than They Hope

19 April 2026
An early forecast for Social Security’s 2027 cost-of-living adjustment held at 2.8%, matching this year’s increase, despite a jump in March inflation. The Senior Citizens League said this would add about $56.69 a month to the average retirement benefit. A rival analyst raised her estimate to 3.2% after the March data. The final COLA will be set in October using third-quarter inflation figures.
Redwire Stock Faces Fresh Selling Pressure as Major Holders File New Sales After $20 Million Marine Corps Order

Redwire Stock Faces Fresh Selling Pressure as Major Holders File New Sales After $20 Million Marine Corps Order

19 April 2026
Redwire Corp’s top shareholders filed to sell up to 5.18 million shares worth nearly $54 million over two days, following news of a $20 million Marine Corps drone order. The stock fell 7.84% Friday to $10.34. AE Red Holdings and Edge Autonomy Ultimate Holdings submitted separate Form 144 notices for the proposed sales. Redwire completed its Edge Autonomy acquisition in June 2025.
Go toTop